
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6655703/publications.pdf Version: 2024-02-01



IÃORC R SCHUIZ

#	Article	IF	CITATIONS
1	Quantitative sensory testing and norepinephrine levels in REM sleep behaviour disorder – a clue to early peripheral autonomic and sensory dysfunction?. Journal of Neurology, 2022, 269, 923-932.	3.6	5
2	Brain age and Alzheimer's-like atrophy are domain-specific predictors of cognitive impairment in Parkinson's disease. Neurobiology of Aging, 2022, 109, 31-42.	3.1	12
3	Erythropoietin Abrogates Post-Ischemic Activation of the NLRP3, NLRC4, and AIM2 Inflammasomes in Microglia/Macrophages in a TAK1-Dependent Manner. Translational Stroke Research, 2022, 13, 462-482.	4.2	17
4	Long-Term Cognitive Decline Related to the Motor Phenotype in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 905-916.	2.8	7
5	Long COVIDâ€19: Objectifying most selfâ€reported neurological symptoms. Annals of Clinical and Translational Neurology, 2022, 9, 141-154.	3.7	67
6	Small-molecule modulators of TRMT2A decrease PolyQ aggregation and PolyQ-induced cell death. Computational and Structural Biotechnology Journal, 2022, 20, 443-458.	4.1	11
7	Heterozygous POLG variant Ser1181Asn co-segregating in a family with autosomal dominant axonal neuropathy, proximal muscle fatigability, ptosis, and ragged red fibers. Neurological Research and Practice, 2022, 4, 5.	2.0	3
8	Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study. Orphanet Journal of Rare Diseases, 2022, 17, 47.	2.7	2
9	The cognitive profile of Friedreich ataxia: a systematic review and meta-analysis. BMC Neurology, 2022, 22, 97.	1.8	7
10	Alpha-Synuclein-Specific Naturally Occurring Antibodies Inhibit Aggregation In Vitro and In Vivo. Biomolecules, 2022, 12, 469.	4.0	9
11	The Role of Vascular Risk Factors in Biomarker-Based AT(N) Groups: A German-Dutch Memory Clinic Study. Journal of Alzheimer's Disease, 2022, 87, 185-195.	2.6	6
12	Classification of patients with embolic stroke of undetermined source into cardioembolic and nonâ€cardioembolic profile subgroups. European Journal of Neurology, 2022, 29, 2275-2282.	3.3	2
13	Increased brain tissue sodium concentration in Friedreich ataxia: A multimodal MR imaging study. NeuroImage: Clinical, 2022, 34, 103025.	2.7	3
14	Imaging patterns of cerebral ischemia in hypereosinophilic syndrome: case report and systematic review. Neurological Sciences, 2022, , .	1.9	0
15	Screen-detected atrial fibrillation predicts mortality in elderly subjects. Europace, 2021, 23, 29-38.	1.7	19
16	Convergent patterns of structural brain changes in rapid eye movement sleep behavior disorder and Parkinson's disease on behalf of the German rapid eye movement sleep behavior disorder study group. Sleep, 2021, 44, .	1.1	26
17	Semi-Automatic MRI Muscle Volumetry to Diagnose and Monitor Hereditary and Acquired Polyneuropathies. Brain Sciences, 2021, 11, 202.	2.3	0
18	Posthypoxic behavioral impairment and mortality of Drosophila melanogaster are associated with high temperatures, enhanced predeath activity and oxidative stress. Experimental and Molecular Medicine, 2021, 53, 264-280.	7.7	9

#	Article	IF	CITATIONS
19	Cerebral Amyloid Angiopathy in Amyloid-Positive Patients from a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2021, 79, 1661-1672.	2.6	8
20	Gaze Deviation and Paresis Score (GPS) Sufficiently Predicts Emergent Large Vessel Occluding Strokes. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105518.	1.6	4
21	Preface to an editorial controversy on αâ€synuclein: How good are cellular models?. Journal of Neurochemistry, 2021, 157, 869-871.	3.9	1
22	Neurological symptoms in COVID-19: a cross-sectional monocentric study of hospitalized patients. Neurological Research and Practice, 2021, 3, 17.	2.0	44
23	YouTube Videos on Parkinson's Disease are a Relevant Source of Patient Information. Journal of Parkinson's Disease, 2021, 11, 833-842.	2.8	4
24	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study. Lancet Neurology, The, 2021, 20, 362-372.	10.2	53
25	Clinical predictors and neural correlates for compromised swallowing safety in Huntington disease. European Journal of Neurology, 2021, 28, 2855-2862.	3.3	8
26	Frailty is an outcome predictor in patients with acute ischemic stroke receiving endovascular treatment. Age and Ageing, 2021, 50, 1785-1791.	1.6	21
27	A Î ² -Wrapin Targeting the N-Terminus of α-Synuclein Monomers Reduces Fibril-Induced Aggregation in Neurons. Frontiers in Neuroscience, 2021, 15, 696440.	2.8	7
28	<scp>COVID</scp> â€19 Vaccineâ€Associated Cerebral Venous Thrombosis in Germany. Annals of Neurology, 2021, 90, 627-639.	5.3	122
29	StrokeWatch: An Instrument for Objective Standardized Real-Time Measurement of Door-to-Needle Times in Acute Ischemic Stroke Treatment. Journal of Stroke and Cerebrovascular Diseases, 2021, 30, 105962.	1.6	2
30	A new CERAD total score with equally weighted z-scores and additional executive and non-amnestic "CERAD-Plus" tests enhances cognitive diagnosis in patients with Parkinson's disease: Evidence from the LANDSCAPE study. Parkinsonism and Related Disorders, 2021, 90, 90-97.	2.2	5
31	Brain Structure and Degeneration Staging in Friedreich Ataxia: <scp>Magnetic Resonance Imaging</scp> Volumetrics from the <scp>ENIGMAâ€Ataxia</scp> Working Group. Annals of Neurology, 2021, 90, 570-583.	5.3	27
32	Cognitive profiles of patients with mild cognitive impairment due to Alzheimer's versus Parkinson's disease defined using a base rate approach: Implications for neuropsychological assessments. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12223.	2.4	4
33	Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome in seven patients with sarcoidosis: a critical discussion of treatment and prognosis. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642110355.	3.5	4
34	Increased neural motor activation and functional reorganization in patients with idiopathic rapid eye movement sleep behavior disorder. Parkinsonism and Related Disorders, 2021, 92, 76-82.	2.2	6
35	Increased Post-Hypoxic Oxidative Stress and Activation of the PERK Branch of the UPR in Trap1-Deficient Drosophila melanogaster Is Abrogated by Metformin. International Journal of Molecular Sciences, 2021, 22, 11586.	4.1	6
36	New Keys to Early Diagnosis: Muscle Echogenicity, Nerve Ultrasound Patterns, Electrodiagnostic, and Clinical Parameters in 150 Patients with Hereditary Polyneuropathies. Neurotherapeutics, 2021, 18, 2425-2435.	4.4	5

#	Article	IF	CITATIONS
37	What can 7T sodium MRI tell us about cellular energy depletion and neurotransmission in Alzheimer's disease?. Alzheimer's and Dementia, 2021, 17, 1843-1854.	0.8	6
38	Changes in brain activation related to visuo-spatial memory after real-time fMRI neurofeedback training in healthy elderly and Alzheimer's disease. Behavioural Brain Research, 2020, 381, 112435.	2.2	8
39	Neurochemical profiles in hereditary ataxias: A meta-analysis of Magnetic Resonance Spectroscopy studies. Neuroscience and Biobehavioral Reviews, 2020, 108, 854-865.	6.1	18
40	Onset features and time to diagnosis in Friedreich's Ataxia. Orphanet Journal of Rare Diseases, 2020, 15, 198.	2.7	27
41	Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurology, The, 2020, 19, 738-747.	10.2	41
42	Quantitative sensory testing predicts histological small fiber neuropathy in postural tachycardia syndrome. Neurology: Clinical Practice, 2020, 10, 428-434.	1.6	20
43	Quantitative sodium imaging using ultraâ€high field magnetic resonance imaging in patients with Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042107.	0.8	1
44	Gaze Palsy as a Manifestation of Todd's Phenomenon: Case Report and Review of the Literature. Brain Sciences, 2020, 10, 298.	2.3	2
45	Microglial-specific depletion of TAK1 is neuroprotective in the acute phase after ischemic stroke. Journal of Molecular Medicine, 2020, 98, 833-847.	3.9	30
46	Effect of a multicomponent exercise intervention on brain metabolism: A randomized controlled trial on Alzheimer's pathology (Dementiaâ€MOVE). Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12032.	3.7	12
47	Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice. EMBO Molecular Medicine, 2020, 12, e11803.	6.9	73
48	Functional Characterization of Atrophy Patterns Related to Cognitive Impairment. Frontiers in Neurology, 2020, 11, 18.	2.4	12
49	Semiâ€automated volumetry of MRI serves as a biomarker in neuromuscular patients. Muscle and Nerve, 2020, 61, 600-607.	2.2	8
50	Structural characteristics of the central nervous system in FriedreichÂataxia: an in vivo spinal cord and brain MRI study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 615-617.	1.9	33
51	Cerebral changes improved by physical activity during cognitive decline: A systematic review on MRI studies. Neurolmage: Clinical, 2019, 23, 101933.	2.7	68
52	Protocol of a randomized, double-blind, placebo-controlled, parallel-group, multicentre study of the efficacy and safety of nicotinamide in patients with Friedreich ataxia (NICOFA). Neurological Research and Practice, 2019, 1, 33.	2.0	14
53	EPO and TMBIM3/GRINA Promote the Activation of the Adaptive Arm and Counteract the Terminal Arm of the Unfolded Protein Response after Murine Transient Cerebral Ischemia. International Journal of Molecular Sciences, 2019, 20, 5421.	4.1	14
54	Cardiac stress after electroconvulsive therapy and spontaneous generalized convulsive seizures: A prospective echocardiographic and blood biomarker study. Epilepsy and Behavior, 2019, 101, 106565.	1.7	1

#	Article	IF	CITATIONS
55	Preface: The energetic brain – a review from students to students. Journal of Neurochemistry, 2019, 151, 137-138.	3.9	0
56	Application of Quantitative Motor Assessments in Friedreich Ataxia and Evaluation of Their Relation to Clinical Measures. Cerebellum, 2019, 18, 896-909.	2.5	9
57	Going beyond the mean: Intraindividual variability of cognitive performance in prodromal and early neurodegenerative disorders. Clinical Neuropsychologist, 2019, 33, 369-389.	2.3	43
58	Prediction of Survival With Longâ€Term Disease Progression in Most Common Spinocerebellar Ataxia. Movement Disorders, 2019, 34, 1220-1227.	3.9	14
59	EPO regulates neuroprotective Transmembrane BAX Inhibitor-1 Motif-containing (TMBIM) family members GRINA and FAIM2 after cerebral ischemia-reperfusion injury. Experimental Neurology, 2019, 320, 112978.	4.1	22
60	Myelinating Glia-Specific Deletion of Fbxo7 in Mice Triggers Axonal Degeneration in the Central Nervous System Together with Peripheral Neuropathy. Journal of Neuroscience, 2019, 39, 5606-5626.	3.6	14
61	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	8.0	10
62	Neurogenic pulmonary edema following seizures: A retrospective computed tomography study. Epilepsy and Behavior, 2019, 94, 112-117.	1.7	10
63	Atypical presentation of anti-Ma2-associated encephalitis with choreiform movement. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e557.	6.0	7
64	Cognitive decline in Parkinson's disease: the impact of the motor phenotype on cognition. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 171-179.	1.9	54
65	Monitoring αâ€synuclein multimerization <i>in vivo</i> . FASEB Journal, 2019, 33, 2116-2131.	0.5	10
66	Brain atrophy measures in preclinical and manifest spinocerebellar ataxia type 2. Annals of Clinical and Translational Neurology, 2018, 5, 128-137.	3.7	45
67	Impact of gender and genetics on emotion processing in Parkinson's disease - A multimodal study. NeuroImage: Clinical, 2018, 18, 305-314.	2.7	32
68	Reviewer selection biases editorial decisions on manuscripts. Journal of Neurochemistry, 2018, 146, 21-46.	3.9	10
69	Relevance of standard intravenous thrombolysis in endovascular stroke therapy of a tertiary stroke center. Acta Neurologica Belgica, 2018, 118, 105-111.	1.1	9
70	Friedreich and dominant ataxias: quantitative differences in cerebellar dysfunction measurements. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 559-565.	1.9	16
71	Faim2 contributes to neuroprotection by erythropoietin in transient brain ischemia. Journal of Neurochemistry, 2018, 145, 258-270.	3.9	15
72	Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurology, The, 2018, 17, 327-334.	10.2	69

#	Article	IF	CITATIONS
73	Early postictal serum lactate concentrations are superior to serum creatine kinase concentrations in distinguishing generalized tonic–clonic seizures from syncopes. Internal and Emergency Medicine, 2018, 13, 749-755.	2.0	23
74	Mechanistic contributions of FBXO7 to Parkinson disease. Journal of Neurochemistry, 2018, 144, 118-127.	3.9	25
75	Open Science Badges in the <i>Journal of Neurochemistry</i> . Journal of Neurochemistry, 2018, 147, 132-136.	3.9	4
76	α1-antitrypsin mitigates NLRP3-inflammasome activation in amyloid β1–42-stimulated murine astrocytes. Journal of Neuroinflammation, 2018, 15, 282.	7.2	53
77	Modern Interdisciplinary and Interhospital Acute Stroke Therapy—What Patients Think About It and What They Really Understand. Journal of Stroke and Cerebrovascular Diseases, 2018, 27, 2669-2676.	1.6	1
78	Risk factors of suicidal ideation in Huntington's disease: literature review and data from Enroll-HD. Journal of Neurology, 2018, 265, 2548-2561.	3.6	37
79	Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brainâ€derived neurotrophic factor. Journal of Neurochemistry, 2018, 147, 678-691.	3.9	17
80	Long-term evolution of patient-reported outcome measures in spinocerebellar ataxias. Journal of Neurology, 2018, 265, 2040-2051.	3.6	34
81	Psychometric Properties of an Abbreviated Version of the Apathy Evaluation Scale for Parkinson Disease (AES-12PD). American Journal of Geriatric Psychiatry, 2018, 26, 1079-1090.	1.2	5
82	Characterization of NaÃ ⁻ ve and Vitamin C-Treated Mouse Schwann Cell Line MSC80: Induction of the Antioxidative Thioredoxin Related Transmembrane Protein 1. Journal of Proteome Research, 2018, 17, 2925-2936.	3.7	9
83	FYCO1 mediates clearance of αâ€synuclein aggregates through a Rab7â€dependent mechanism. Journal of Neurochemistry, 2018, 146, 474-492.	3.9	19
84	Nonataxia symptoms in Friedreich Ataxia. Neurology, 2018, 91, e917-e930.	1.1	46
85	Brain imaging findings in idiopathic REM sleep behavior disorder (RBD) – A systematic review on potential biomarkers for neurodegeneration. Sleep Medicine Reviews, 2017, 34, 23-33.	8.5	76
86	Linking amyotrophic lateral sclerosis and spinal muscular atrophy through <scp>RNA</scp> â€ŧranscriptome homeostasis: a genomics perspective. Journal of Neurochemistry, 2017, 141, 12-30.	3.9	25
87	Psychometric properties of the apathy evaluation scale in patients with Parkinson's disease. International Journal of Methods in Psychiatric Research, 2017, 26, .	2.1	10
88	Sodiumâ€dependent Vitamin C transporter 2 deficiency impairs myelination and remyelination after injury: Roles of collagen and demethylation. Glia, 2017, 65, 1186-1200.	4.9	13
89	Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. Journal of Neurology, 2017, 264, 1193-1203.	3.6	41
90	Unobtrusive Nocturnal Heartbeat Monitoring by a Ballistocardiographic Sensor in Patients with Sleep Disordered Breathing. Scientific Reports, 2017, 7, 13175.	3.3	31

#	Article	IF	CITATIONS
91	Frequent genes in rare diseases: panelâ€based next generation sequencing to disclose causal mutations in hereditary neuropathies. Journal of Neurochemistry, 2017, 143, 507-522.	3.9	68
92	Vaccination strategies in tauopathies and synucleinopathies. Journal of Neurochemistry, 2017, 143, 467-488.	3.9	30
93	Body Mass Index Decline Is Related to Spinocerebellar Ataxia Disease Progression. Movement Disorders Clinical Practice, 2017, 4, 689-697.	1.5	25
94	The malleable brain - An educational review from students to students. Journal of Neurochemistry, 2017, 142, 788-789.	3.9	3
95	Sporadic late-onset nemaline myopathy: clinico-pathological characteristics and review of 76 cases. Orphanet Journal of Rare Diseases, 2017, 12, 86.	2.7	77
96	Grading of proximal internal carotid artery (ICA) stenosis by Doppler/duplex ultrasound (DUS) and computed tomographic angiography (CTA): correlation and interrater reliability in real-life practice. Acta Neurologica Belgica, 2017, 117, 183-188.	1.1	9
97	Cognitive Improvement and Brain Changes after Real-Time Functional MRI Neurofeedback Training in Healthy Elderly and Prodromal Alzheimer's Disease. Frontiers in Neurology, 2017, 8, 384.	2.4	41
98	Metabolic Syndrome, Neurotoxic 1-Deoxysphingolipids and Nervous Tissue Inflammation in Chronic Idiopathic Axonal Polyneuropathy (CIAP). PLoS ONE, 2017, 12, e0170583.	2.5	13
99	Anterior sacral meningocele infected with Fusobacterium in a patient with recently diagnosed colorectal carcinoma $\hat{a} \in $ a case report. BMC Neurology, 2017, 17, 212.	1.8	2
100	Clinical and biometrical 12-month follow-up in patients after reconstruction of the sural nerve biopsy defect by the collagen-based nerve guide Neuromaix. European Journal of Medical Research, 2017, 22, 34.	2.2	43
101	Posterior Cortical Atrophy. Alzheimer Disease and Associated Disorders, 2016, 30, 276-280.	1.3	2
102	Rab7 induces clearance of αâ€synuclein aggregates. Journal of Neurochemistry, 2016, 138, 758-774.	3.9	63
103	Novel genetic and neuropathological insights in neurogenic muscle weakness, ataxia, and retinitis pigmentosa (NARP). Muscle and Nerve, 2016, 54, 328-333.	2.2	22
104	Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1099-1105.	1.9	76
105	Synaptopathies: synaptic dysfunction in neurological disorders - A review written by students for students, and a story of success for ISN schools. Journal of Neurochemistry, 2016, 138, 783-784.	3.9	8
106	Verbal memory declines more in female patients with Parkinson's disease: the importance of gender-corrected normative data. Psychological Medicine, 2016, 46, 2275-2286.	4.5	14
107	Apolipoprotein E ε4 does not affect cognitive performance in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2016, 29, 112-116.	2.2	22
108	Ret is essential to mediate GDNF's neuroprotective and neuroregenerative effect in a Parkinson disease mouse model. Cell Death and Disease, 2016, 7, e2359-e2359.	6.3	67

#	Article	IF	CITATIONS
109	Loss of <scp>FBXO</scp> 7 (<scp>PARK</scp> 15) results in reduced proteasome activity and models a parkinsonismâ€like phenotype in mice. EMBO Journal, 2016, 35, 2008-2025.	7.8	65
110	Underestimated associated features in <scp>CMT</scp> neuropathies: clinical indicators for the causative gene?. Brain and Behavior, 2016, 6, e00451.	2.2	25
111	Current and experimental treatments of Parkinson disease: A guide for neuroscientists. Journal of Neurochemistry, 2016, 139, 325-337.	3.9	268
112	199Âyears of Parkinson disease – what have we learned and what is the path to the future?. Journal of Neurochemistry, 2016, 139, 3-7.	3.9	23
113	Tubular aggregates in autoimmune Lambert–Eaton myasthenic syndrome. Neuromuscular Disorders, 2016, 26, 880-884.	0.6	3
114	Mice lacking Faim2 show increased cell death in the <scp>MPTP</scp> mouse model of Parkinson disease. Journal of Neurochemistry, 2016, 139, 848-857.	3.9	14
115	Reflections on 60Âyears of publication of the Journal of Neurochemistry. Journal of Neurochemistry, 2016, 139, 7-16.	3.9	4
116	60ÂYears of the Journal of Neurochemistry. Journal of Neurochemistry, 2016, 139, 5-6.	3.9	0
117	The impact of fraudulent and irreproducible data to the translational research crisis – solutions and implementation. Journal of Neurochemistry, 2016, 139, 253-270.	3.9	41
118	Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study. Lancet Neurology, The, 2016, 15, 1346-1354.	10.2	117
119	A Learned Society's Perspective on Publishing. Journal of Neurochemistry, 2016, 139, 17-23.	3.9	10
120	D26â€Pathological tau signal in huntington's disease – an in vivo [18F]-AV-1451 pet imaging report. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A44.1-A44.	1.9	2
121	D14â€Resting-state connectivity changes in huntington's disease: a follow-up study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A38.3-A39.	1.9	0
122	Cognition in Friedreich's ataxia: a behavioral and multimodal imaging study. Annals of Clinical and Translational Neurology, 2016, 3, 572-587.	3.7	50
123	Standardized Assessment of Hereditary Ataxia Patients in Clinical Studies. Movement Disorders Clinical Practice, 2016, 3, 230-240.	1.5	13
124	Neurothrombectomy in acute ischaemic stroke: a prospective singleâ€centre study and comparison with randomized controlled trials. European Journal of Neurology, 2016, 23, 807-816.	3.3	30
125	Reduced intraepidermal nerve fiber density in patients with REM sleep behavior disorder. Parkinsonism and Related Disorders, 2016, 29, 10-16.	2.2	29
126	Lactate as a diagnostic marker in transient loss of consciousness. Seizure: the Journal of the British Epilepsy Association, 2016, 40, 71-75.	2.0	56

#	Article	IF	CITATIONS
127	Risk profile and treatment options of acute ischemic in-hospital stroke. Journal of Neurology, 2016, 263, 550-557.	3.6	23
128	Expanded phenotypic spectrum of the m.8344A>G "MERRF―mutation: data from the German mitoNET registry. Journal of Neurology, 2016, 263, 961-972.	3.6	77
129	Analysis of drug-related problems in three departments of a German University hospital. International Journal of Clinical Pharmacy, 2016, 38, 119-126.	2.1	47
130	Cardiovascular causes of emergency neurology presenting to an ICU. Perfusion (United Kingdom), 2016, 31, 271-280.	1.0	2
131	Increased Cerebral Water Content in Hemodialysis Patients. PLoS ONE, 2015, 10, e0122188.	2.5	22
132	GAD Antibodies as Key Link Between Chronic Intestinal Pseudoobstruction, Autonomic Neuropathy, and Limb Stiffness in a Nondiabetic Patient. Medicine (United States), 2015, 94, e1265.	1.0	10
133	Elevation of plasma 1â€deoxyâ€sphingolipids in type 2 diabetes mellitus: a susceptibility to neuropathy?. European Journal of Neurology, 2015, 22, 806.	3.3	44
134	Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data. Lancet Neurology, The, 2015, 14, 174-182.	10.2	159
135	Quantifiable evaluation of cerebellar signs in children. Neurology, 2015, 84, 1225-1232.	1.1	8
136	Impaired retrograde transport by the Dynein/Dynactin complex contributes to Tau-induced toxicity. Human Molecular Genetics, 2015, 24, 3623-3637.	2.9	58
137	Adjuvant Granulocyte Colony-Stimulating Factor Therapy Results in Improved Spatial Learning and Stimulates Hippocampal Neurogenesis in a Mouse Model of Pneumococcal Meningitis. Journal of Neuropathology and Experimental Neurology, 2015, 74, 85-94.	1.7	13
138	Long-term disease progression in spinocerebellar ataxia types 1, 2, 3, and 6: a longitudinal cohort study. Lancet Neurology, The, 2015, 14, 1101-1108.	10.2	213
139	Functional connectivity modeling of consistent cortico-striatal degeneration in Huntington's disease. NeuroImage: Clinical, 2015, 7, 640-652.	2.7	27
140	Nuclear import factor transportin and arginine methyltransferase 1 modify FUS neurotoxicity in Drosophila. Neurobiology of Disease, 2015, 74, 76-88.	4.4	36
141	Consensus Paper: Radiological Biomarkers of Cerebellar Diseases. Cerebellum, 2015, 14, 175-196.	2.5	42
142	Specific and disease stage-dependent episodic memory-related brain activation patterns in Alzheimer's disease: a coordinate-based meta-analysis. Brain Structure and Function, 2015, 220, 1555-1571.	2.3	46
143	The Montreal Cognitive Assessment (MoCA) - A Sensitive Screening Instrument for Detecting Cognitive Impairment in Chronic Hemodialysis Patients. PLoS ONE, 2014, 9, e106700.	2.5	130
144	Consensus clinical management guidelines for Friedreich ataxia. Orphanet Journal of Rare Diseases, 2014, 9, 184.	2.7	76

#	Article	IF	CITATIONS
145	The Proximal Medial Sural Nerve Biopsy Model: A Standardised and Reproducible Baseline Clinical Model for the Translational Evaluation of Bioengineered Nerve Guides. BioMed Research International, 2014, 2014, 1-11.	1.9	17
146	Neural correlates of impaired emotion processing in manifest Huntington's disease. Social Cognitive and Affective Neuroscience, 2014, 9, 671-680.	3.0	44
147	Modulation of Hippocampal Neuroplasticity by Fas/CD95 Regulatory Protein 2 (Faim2) in the Course of Bacterial Meningitis. Journal of Neuropathology and Experimental Neurology, 2014, 73, 2-13.	1.7	18
148	Evidence of the Sensitivity of the MoCA Alternate Forms in Monitoring Cognitive Change in Early Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders, 2014, 37, 95-103.	1.5	43
149	<scp>CDK</scp> 5 protects from caspaseâ€induced Ataxinâ€3 cleavage and neurodegeneration. Journal of Neurochemistry, 2014, 129, 1013-1023.	3.9	20
150	Clinical significance of post-interventional cerebral hyperdensities after endovascular mechanical thrombectomy in acute ischaemic stroke. Neuroradiology, 2014, 56, 41-50.	2.2	35
151	Altered restingâ€state connectivity in Huntington's Disease. Human Brain Mapping, 2014, 35, 2582-2593.	3.6	82
152	Unusual multisystemic involvement and a novel BAG3 mutation revealed by NGS screening in a large cohort of myofibrillar myopathies. Orphanet Journal of Rare Diseases, 2014, 9, 121.	2.7	38
153	UBE2E Ubiquitin-conjugating Enzymes and Ubiquitin Isopeptidase Y Regulate TDP-43 Protein Ubiquitination. Journal of Biological Chemistry, 2014, 289, 19164-19179.	3.4	62
154	The processing of lexical ambiguity in healthy ageing and Parkinson× ³ s disease: Role of cortico-subcortical networks. Brain Research, 2014, 1581, 51-63.	2.2	12
155	Novel TPM3 mutation in a family with cap myopathy and review of the literature. Neuromuscular Disorders, 2014, 24, 117-124.	0.6	18
156	Clinical Predictors of Individual Cognitive Fluctuations in Patients Undergoing Hemodialysis. American Journal of Kidney Diseases, 2014, 64, 434-442.	1.9	50
157	Evidence for gender differences in cognition, emotion and quality of life in Parkinson's disease?. , 2014, 5, 63-75.		33
158	Cognitive effects of deep brain stimulation for essential tremor: evaluation at 1 and 6Âyears. Journal of Neural Transmission, 2013, 120, 1569-1577.	2.8	23
159	Differentiated parietal connectivity of frontal regions for "what―and "where―memory. Brain Structure and Function, 2013, 218, 1551-1567.	2.3	86
160	TRAP1 rescues PINK1 loss-of-function phenotypes. Human Molecular Genetics, 2013, 22, 2829-2841.	2.9	81
161	Biological and clinical characteristics of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 in the longitudinal RISCA study: analysis of baseline data. Lancet Neurology, The, 2013, 12, 650-658.	10.2	167
162	Drosophila melanogaster as a model organism for Alzheimer's disease. Molecular Neurodegeneration, 2013, 8, 35.	10.8	171

#	Article	IF	CITATIONS
163	Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. Journal of Neurology, 2013, 260, 3093-3108.	3.6	71
164	Coâ€enzyme Q ₁₀ and idebenone use in Friedreich's ataxia. Journal of Neurochemistry, 2013, 126, 125-141.	3.9	97
165	Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice. Neurobiology of Aging, 2013, 34, 589-601.	3.1	16
166	Novel <i>FHL1</i> mutation in a family with reducing body myopathy. Muscle and Nerve, 2013, 47, 127-134.	2.2	23
167	<i>Drosophila</i> as a screening tool to study human neurodegenerative diseases. Journal of Neurochemistry, 2013, 127, 453-460.	3.9	86
168	150Âyears of Friedreich Ataxia: from its discovery to therapy. Journal of Neurochemistry, 2013, 126, 1-3.	3.9	17
169	Consistent Neurodegeneration and Its Association with Clinical Progression in Huntington's Disease: A Coordinate-Based Meta-Analysis. Neurodegenerative Diseases, 2013, 12, 23-35.	1.4	64
170	Rating disease progression of Friedreich's ataxia by the International Cooperative Ataxia Rating Scale: analysis of a 603-patient database. Brain, 2013, 136, 259-268.	7.6	48
171	Genotype-specific patterns of atrophy progression are more sensitive than clinical decline in SCA1, SCA3 and SCA6. Brain, 2013, 136, 905-917.	7.6	128
172	PML in a Patient Treated with Fumaric Acid. New England Journal of Medicine, 2013, 368, 1657-1658.	27.0	176
173	A Global In Vivo Drosophila RNAi Screen Identifies a Key Role of Ceramide Phosphoethanolamine for Glial Ensheathment of Axons. PLoS Genetics, 2013, 9, e1003980.	3.5	44
174	Diagnostic challenge and therapeutic dilemma in necrotizing myopathy. Neurology, 2013, 81, 932-935.	1.1	14
175	Teaching Neuro <i>Images</i> : Combined retinal and cerebral hyperperfusion syndrome after carotid thromboendarterectomy. Neurology, 2013, 81, e166-7.	1.1	1
176	Molecular imaging and its applications: visualization beyond imagination. Journal of Neurochemistry, 2013, 127, 575-577.	3.9	0
177	Monitoring progression in Friedreich ataxia (<scp>FRDA</scp>): the use of clinical scales. Journal of Neurochemistry, 2013, 126, 118-124.	3.9	51
178	Yeast, fish, fly – models to study the pathogenesis of proteinopathies and screen for interventions. Journal of Neurochemistry, 2013, 127, 434-434.	3.9	0
179	Case Reports of PML in Patients Treated for Psoriasis. New England Journal of Medicine, 2013, 369, 1080-1082.	27.0	45
180	Common data elements for clinical research in Friedreich's ataxia. Movement Disorders, 2013, 28, 190-195.	3.9	14

#	Article	IF	CITATIONS
181	Diminished Activation of Motor Working-Memory Networks in Parkinson's Disease. PLoS ONE, 2013, 8, e61786.	2.5	29
182	Morphological spectrum and clinical features of myopathies with tubular aggregates. Histology and Histopathology, 2013, 28, 1041-54.	0.7	16
183	The Mitochondrial Chaperone Protein TRAP1 Mitigates α-Synuclein Toxicity. PLoS Genetics, 2012, 8, e1002488.	3.5	120
184	The Heart in Friedreich Ataxia. Circulation, 2012, 125, 1626-1634.	1.6	119
185	Clinical data and characterization of the liver conditional mouse model exclude neoplasia as a non-neurological manifestation associated with Friedreich's ataxia. DMM Disease Models and Mechanisms, 2012, 5, 860-9.	2.4	34
186	Alternate-Form Reliability of the Montreal Cognitive Assessment Screening Test in a Clinical Setting. Dementia and Geriatric Cognitive Disorders, 2012, 33, 379-384.	1.5	93
187	Myopathy with lobulated fibers, cores, and rods caused by a mutation in collagen VI. Neurology, 2012, 79, 2288-2290.	1.1	7
188	Efficient Gene Therapy for Parkinson's Disease Using Astrocytes as Hosts for Localized Neurotrophic Factor Delivery. Molecular Therapy, 2012, 20, 534-543.	8.2	82
189	Receptor for advanced glycation endproducts (RAGE) deficiency protects against MPTP toxicity. Neurobiology of Aging, 2012, 33, 2478-2490.	3.1	66
190	Effects of selegiline and rasagiline on disease progression in Parkinson's disease. Basal Ganglia, 2012, 2, S41-S45.	0.3	5
191	Modelling neural correlates of working memory: A coordinate-based meta-analysis. NeuroImage, 2012, 60, 830-846.	4.2	777
192	Investigating function and connectivity of morphometric findings — Exemplified on cerebellar atrophy in spinocerebellar ataxia 17 (SCA17). NeuroImage, 2012, 62, 1354-1366.	4.2	72
193	Increased brain tissue sodium concentration in Huntington's Disease — A sodium imaging study at 4T. NeuroImage, 2012, 63, 517-524.	4.2	67
194	The Cancer Stem Cell Subtype Determines Immune Infiltration of Glioblastoma. Stem Cells and Development, 2012, 21, 2753-2761.	2.1	79
195	Feasibility of Prehospital Teleconsultation in Acute Stroke – A Pilot Study in Clinical Routine. PLoS ONE, 2012, 7, e36796.	2.5	91
196	Efficacy of clinically relevant temozolomide dosing schemes in glioblastoma cancer stem cell lines. Journal of Neuro-Oncology, 2012, 109, 45-52.	2.9	41
197	Spinocerebellar Ataxia Types 1, 2, 3 and 6: the Clinical Spectrum of Ataxia and Morphometric Brainstem and Cerebellar Findings. Cerebellum, 2012, 11, 155-166.	2.5	74
198	A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice. Neurobiology of Disease, 2012, 45, 591-600.	4.4	22

#	Article	IF	CITATIONS
199	Neuroanatomic changes and their association with cognitive decline in mild cognitive impairment: a meta-analysis. Brain Structure and Function, 2012, 217, 115-125.	2.3	67
200	Large-Scale Screen for Modifiers of Ataxin-3-Derived Polyglutamine-Induced Toxicity in Drosophila. PLoS ONE, 2012, 7, e47452.	2.5	38
201	P3.36. Phenotypic spectrum in myopathies with tubular aggregates. Neuromuscular Disorders, 2011, 21, 692-693.	0.6	0
202	Sustained Effects of Once-Daily Memantine Treatment on Cognition and Functional Communication Skills in Patients with Moderate to Severe Alzheimer's Disease: Results of a 16-Week Open-Label Trial. Journal of Alzheimer's Disease, 2011, 25, 463-475.	2.6	25
203	Basic science in Parkinson's disease: its impact on clinical practice. Journal of Neurology, 2011, 258, 299-306.	3.6	6
204	Chemoresistance of glioblastoma cancer stem cells - much more complex than expected. Molecular Cancer, 2011, 10, 128.	19.2	265
205	Depression comorbidity in spinocerebellar ataxia. Movement Disorders, 2011, 26, 870-876.	3.9	69
206	The natural history of spinocerebellar ataxia type 1, 2, 3, and 6. Neurology, 2011, 77, 1035-1041.	1.1	259
207	Fas/CD95 Regulatory Protein Faim2 Is Neuroprotective after Transient Brain Ischemia. Journal of Neuroscience, 2011, 31, 225-233.	3.6	43
208	Parkinson's Disease and Dementia: A Longitudinal Study (DEMPARK). Neuroepidemiology, 2011, 37, 168-176.	. 2.3	47
209	Aorto-left-ventricular tunnel. Neurology, 2011, 76, 2129-2129.	1.1	0
210	Targeted Ablation of Oligodendrocytes Triggers Axonal Damage. PLoS ONE, 2011, 6, e22735.	2.5	47
211	Involvement of the human ventrolateral thalamus in olfaction. Journal of Neurology, 2010, 257, 2037-2043.	3.6	13
212	Transgenic overexpression of the alpha-synuclein interacting protein synphilin-1 leads to behavioral and neuropathological alterations in mice. Neurogenetics, 2010, 11, 107-120.	1.4	18
213	Selfâ€rated health status in spinocerebellar ataxia—Results from a European multicenter study. Movement Disorders, 2010, 25, 587-595.	3.9	74
214	Differential pattern of brainâ€specific CSF proteins tau and amyloidâ€beta in Parkinsonian syndromes. Movement Disorders, 2010, 25, 1284-1288.	3.9	44
215	PKC links G _q â€coupled receptors to DATâ€mediated dopamine release. Journal of Neurochemistry, 2010, 114, 587-596.	3.9	25
216	Knockdown of transactive response DNA-binding protein (TDP-43) downregulates histone deacetylase 6. EMBO Journal, 2010, 29, 209-221.	7.8	200

#	Article	IF	CITATIONS
217	TDP-43-Mediated Neuron Loss In Vivo Requires RNA-Binding Activity. PLoS ONE, 2010, 5, e12247.	2.5	166
218	Responsiveness of different rating instruments in spinocerebellar ataxia patients. Neurology, 2010, 74, 678-684.	1.1	153
219	Effects of deep brain stimulation of the cerebellothalamic pathways on the sense of smell. Experimental Neurology, 2010, 222, 144-152.	4.1	16
220	Visualization, quantification and correlation of brain atrophy with clinical symptoms in spinocerebellar ataxia types 1, 3 and 6. NeuroImage, 2010, 49, 158-168.	4.2	162
221	The Yeast HtrA Orthologue Ynm3 Is a Protease with Chaperone Activity that Aids Survival Under Heat Stress. Molecular Biology of the Cell, 2009, 20, 68-77.	2.1	32
222	Comparison of three clinical rating scales in Friedreich ataxia (FRDA). Movement Disorders, 2009, 24, 1779-1784.	3.9	131
223	Clinical experience with high-dose idebenone in Friedreich ataxia. Journal of Neurology, 2009, 256, 42-45.	3.6	58
224	Pre-fibrillar α-synuclein variants with impaired β-structure increase neurotoxicity in Parkinson's disease models. EMBO Journal, 2009, 28, 3256-3268.	7.8	411
225	Aggregate formation and toxicity by wildâ€ŧype and R621C synphilinâ€1 in the nigrostriatal system of mice using adenoviral vectors. Journal of Neurochemistry, 2009, 108, 139-146.	3.9	27
226	BAG1 modulates huntingtin toxicity, aggregation, degradation, and subcellular distribution. Journal of Neurochemistry, 2009, 111, 801-807.	3.9	25
227	Diagnosis and treatment of Friedreich ataxia: a European perspective. Nature Reviews Neurology, 2009, 5, 222-234.	10.1	231
228	CD95/Fas in the Brain—Not Just a Killer. Cell Stem Cell, 2009, 5, 128-130.	11.1	12
229	M.P.1.02 SNT-MC17/idebenone in the treatment of Friedreich's ataxia: Preliminary safety data from a 12-month European randomized, placebo-controlled study. Neuromuscular Disorders, 2009, 19, 546.	0.6	0
230	Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum, 2008, 7, 204-214.	2.5	67
231	Long-term EMG recordings differentiate between parkinsonian and essential tremor. Journal of Neurology, 2008, 255, 103-111.	3.6	68
232	Lewy body dementia and Parkinson's disease with dementia. Journal of Neurology, 2008, 255, 39-47.	3.6	45
233	Update on the pathogenesis of Parkinson's disease. Journal of Neurology, 2008, 255, 3-7.	3.6	258
234	Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo. Journal of Neurochemistry, 2008, 74, 2213-2216.	3.9	299

#	Article	IF	CITATIONS
235	Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. Journal of Neurochemistry, 2008, 77, 263-273.	3.9	4
236	Dopamine mediates striatal malonate toxicity via dopamine transporter-dependent generation of reactive oxygen species and D2 but not D1 receptor activation. Journal of Neurochemistry, 2008, 79, 63-70.	3.9	47
237	Bilateral changes in neuronal activity of the basal ganglia in the unilateral 6â€hydroxydopamine rat model. Journal of Neuroscience Research, 2008, 86, 1388-1396.	2.9	39
238	Tatâ€Hsp70 protects dopaminergic neurons in midbrain cultures and in the substantia nigra in models of Parkinson's disease. Journal of Neurochemistry, 2008, 105, 853-864.	3.9	85
239	Accumulation and clearance of αâ€synuclein aggregates demonstrated by timeâ€lapse imaging. Journal of Neurochemistry, 2008, 106, 529-540.	3.9	66
240	Influence of SORL1 gene variants: Association with CSF amyloid-β products in probable Alzheimer's disease. Neuroscience Letters, 2008, 440, 68-71.	2.1	43
241	Death receptor Fas (CD95) signaling in the central nervous system: tuning neuroplasticity?. Trends in Neurosciences, 2008, 31, 478-486.	8.6	41
242	Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting. Science, 2008, 320, 520-523.	12.6	254
243	Neurodegeneration and Motor Dysfunction in a Conditional Model of Parkinson's Disease. Journal of Neuroscience, 2008, 28, 2471-2484.	3.6	164
244	Mitochondrial Protein Quality Control by the Proteasome Involves Ubiquitination and the Protease Omi. Journal of Biological Chemistry, 2008, 283, 12681-12685.	3.4	145
245	Magnetic resonance imaging in spinocerebellar ataxias. Cerebellum, 2008, 7, 1-11.	2.5	0
246	Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8161-8166.	7.1	190
247	The proteasomal subunit S6 ATPase is a novel synphilinâ€1 interacting protein—implications for Parkinson's disease. FASEB Journal, 2007, 21, 1759-1767.	0.5	48
248	RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 20049-20054.	7.1	53
249	Mechanisms of neurodegeneration in idiopathic Parkinson's disease. Parkinsonism and Related Disorders, 2007, 13, S306-S308.	2.2	35
250	Silencing of the <i>Pink1</i> Gene Expression by Conditional RNAi Does Not Induce Dopaminergic Neuron Death in Mice. International Journal of Biological Sciences, 2007, 3, 242-250.	6.4	80
251	Extracellular domain splice variants of a transforming protein tyrosine phosphatase ? mutant differentially activate Src-kinase dependent focus formation. Genes To Cells, 2007, 12, 63-73.	1.2	12
252	Bloodâ€based neurochemical diagnosis of vascular dementia: a pilot study. Journal of Neurochemistry, 2007, 103, 467-474.	3.9	55

#	Article	IF	CITATIONS
253	Membrane-permeable Bcl-xLprevents MPTP-induced dopaminergic neuronal loss in the substantia nigra. Journal of Neurochemistry, 2007, 104, 071108171001009-???.	3.9	20
254	Transient expression of Nxf, a bHLH–PAS transactivator induced by neuronal preconditioning, confers neuroprotection in cultured cells. Brain Research, 2007, 1135, 1-11.	2.2	26
255	Cortical stimulation mapping using epidurally implanted thin-film microelectrode arrays. Journal of Neuroscience Methods, 2007, 161, 118-125.	2.5	60
256	Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. European Journal of Neuroscience, 2006, 24, 2275-2282.	2.6	60
257	Granulocyte olony stimulating factor is neuroprotective in a model of Parkinson's disease. Journal of Neurochemistry, 2006, 97, 675-686.	3.9	109
258	The multidrug resistance protein 1 (Mrp1), but not Mrp5, mediates export of glutathione and glutathione disulfide from brain astrocytes. Journal of Neurochemistry, 2006, 97, 373-384.	3.9	165
259	Ergoline and non-ergoline derivatives in the treatment of Parkinson's disease. Journal of Neurology, 2006, 253, iv36-iv38.	3.6	23
260	Cholesterol depletion reduces aggregation of amyloid-beta peptide in hippocampal neurons. Neurobiology of Disease, 2006, 23, 573-577.	4.4	80
261	Visualization and quantification of disease progression in multiple system atrophy. Movement Disorders, 2006, 21, 1674-1681.	3.9	53
262	Penguins and hummingbirds: Midbrain atrophy in progressive supranuclear palsy. Neurology, 2006, 66, 949-950.	1.1	74
263	Statin Therapy at Carotid Angioplasty and Stent Placement: Effect on Procedure-related Stroke, Myocardial Infarction, and Death. Radiology, 2006, 240, 145-151.	7.3	81
264	Clinical and Magnetic Resonance Imaging Characteristics of Sporadic Cerebellar Ataxia. Archives of Neurology, 2005, 62, 981-5.	4.5	45
265	Diagnosis and management of dementia with Lewy bodies. Neurology, 2005, 65, 1863-1872.	1.1	4,604
266	Unilateral lesion of the pedunculopontine nucleus induces hyperactivity in the subthalamic nucleus and substantia nigra in the rat. European Journal of Neuroscience, 2005, 22, 2283-2294.	2.6	43
267	Neurodegeneration. , 2005, , 335-355.		Ο
268	Apoptosis in neurodegenerative diseases. , 2005, , 80-93.		0
269	Molekulare Ursachen der Parkinson Krankheit. E-Neuroforum, 2005, 11, 112-119.	0.1	0
270	Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease. Human Molecular Genetics, 2005, 14, 2099-2111.	2.9	514

#	Article	IF	CITATIONS
271	FasL (CD95L/APO-1L) Resistance of Neurons Mediated by Phosphatidylinositol 3-Kinase-Akt/Protein Kinase B-Dependent Expression of Lifeguard/Neuronal Membrane Protein 35. Journal of Neuroscience, 2005, 25, 6765-6774.	3.6	53
272	Palmitoylation is a sorting determinant for transport to the myelin membrane. Journal of Cell Science, 2005, 118, 2415-2423.	2.0	46
273	Systematic Review of Early Recurrent Stenosis After Carotid Angioplasty and Stenting. Stroke, 2005, 36, 367-373.	2.0	139
274	Clinical Predictors of Transient Ischemic Attack, Stroke, or Death Within 30 Days of Carotid Angioplasty and Stenting. Stroke, 2005, 36, 787-791.	2.0	73
275	Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with ll̂®Bα induction and block of NFήB and iNOS activation. Journal of Neurochemistry, 2004, 88, 494-501.	3.9	347
276	Repetitive Bilateral Arm Training and Motor Cortex Activation in Chronic Stroke. JAMA - Journal of the American Medical Association, 2004, 292, 1853.	7.4	487
277	MRI-based volumetric differentiation of sporadic cerebellar ataxia. Brain, 2004, 127, 175-181.	7.6	44
278	Motor Skill Learning Depends on Protein Synthesis in Motor Cortex after Training. Journal of Neuroscience, 2004, 24, 6515-6520.	3.6	140
279	Protein Synthesis Inhibition Blocks Consolidation of an Acrobatic Motor Skill. Learning and Memory, 2004, 11, 379-382.	1.3	21
280	Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice. Molecular and Cellular Biology, 2004, 24, 9848-9862.	2.3	367
281	Chemotherapyâ€induced cell death in primary cerebellar granule neurons but not in astrocytes: <i>in vitro</i> paradigm of differential neurotoxicity. Journal of Neurochemistry, 2004, 91, 1067-1074.	3.9	54
282	Senataxin, the ortholog of a yeast RNA helicase, is mutant in ataxia-ocular apraxia 2. Nature Genetics, 2004, 36, 225-227.	21.4	454
283	Intracellular acidification by inhibition of the Na+/H+-exchanger leads to caspase-independent death of cerebellar granule neurons resembling paraptosis. Cell Death and Differentiation, 2004, 11, 760-770.	11.2	53
284	Deep brain stimulation. Cell and Tissue Research, 2004, 318, 275-288.	2.9	231
285	Cellular pathology of Parkinson?s disease: astrocytes, microglia and inflammation. Cell and Tissue Research, 2004, 318, 149-161.	2.9	327
286	Gene therapy in Parkinson?s disease. Cell and Tissue Research, 2004, 318, 243-260.	2.9	8
287	Neuronal pathology in Parkinson?s disease. Cell and Tissue Research, 2004, 318, 135-147.	2.9	79
288	The dopaminergic nigrostriatal system: development, physiology, disease. Cell and Tissue Research, 2004, 318, 3-3.	2.9	3

#	Article	IF	CITATIONS
289	New developments in diagnosis and treatment of Parkinson?s disease?From basic science to clinical applications. Journal of Neurology, 2004, 251, VI/33-8.	3.6	6
290	Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Human Mutation, 2004, 24, 321-329.	2.5	117
291	Comparison of angioplasty and stenting with cerebral protection versus endarterectomy for treatment of internal carotid artery stenosis in elderly patients. Journal of Vascular Surgery, 2004, 40, 945-951.	1.1	74
292	Characterization of motor skill and instrumental learning time scales in a skilled reaching task in rat. Behavioural Brain Research, 2004, 155, 249-256.	2.2	71
293	Short and long-term motor skill learning in an accelerated rotarod training paradigm. Neurobiology of Learning and Memory, 2004, 81, 211-216.	1.9	172
294	Magnetic resonance imaging-based volumetry differentiates progressive supranuclear palsy from corticobasal degeneration. NeuroImage, 2004, 21, 714-724.	4.2	145
295	Lesion location alters brain activation in chronically impaired stroke survivors. NeuroImage, 2004, 21, 924-935.	4.2	130
296	Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily. Journal of Clinical Investigation, 2004, 114, 1741-1751.	8.2	247
297	Adenoviral (full-length) Apo2L/TRAIL gene transfer is an ineffective treatment strategy for malignant glioma. Journal of Neuro-Oncology, 2003, 61, 7-15.	2.9	14
298	Therapeutic strategies for Parkinson's disease based on data derived from genetic research. Journal of Neurology, 2003, 250, i3-i10.	3.6	4
299	Gene dosage-dependent effects of bcl-2 expression on cellular survival and redox status. Free Radical Biology and Medicine, 2003, 34, 1517-1530.	2.9	15
300	Relation between Regional Functional MRI Activation and Vascular Reactivity to Carbon Dioxide during Normal Aging. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 565-573.	4.3	100
301	Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicology Letters, 2003, 139, 135-151.	0.8	102
302	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	2.9	329
303	Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. Human Molecular Genetics, 2003, 12, 1223-1231.	2.9	124
304	Early Outcome of Carotid Angioplasty and Stenting versus Carotid Endarterectomy in a Single Academic Center. Cerebrovascular Diseases, 2003, 15, 84-89.	1.7	39
305	Early Outcome of Carotid Angioplasty and Stenting With and Without Cerebral Protection Devices. Stroke, 2003, 34, 813-819.	2.0	551
306	Transgenic rat model of Huntington's disease. Human Molecular Genetics, 2003, 12, 617-624.	2.9	58

#	Article	IF	CITATIONS
307	Very Bright Dorsal Columns. Archives of Neurology, 2002, 59, 147.	4.5	3
308	Overexpression of the myelin proteolipid protein leads to accumulation of cholesterol and proteolipid protein in endosomes/lysosomes. Journal of Cell Biology, 2002, 157, 327-336.	5.2	154
309	Potential Synergistic Protection of Retinal Ganglion Cells from Axotomy-Induced Apoptosis by Adenoviral Administration of Glial Cell Line-Derived Neurotrophic Factor and X-Chromosome-Linked Inhibitor of Apoptosis. Neurobiology of Disease, 2002, 11, 123-133.	4.4	61
310	Parkinson's disease: one biochemical pathway to fit all genes?. Trends in Molecular Medicine, 2002, 8, 236-240.	6.7	68
311	Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt. Journal of Neuroscience, 2002, 22, 6401-6407.	3.6	279
312	Caspases in Neurodegeneration. , 2002, , 179-187.		0
313	Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26â€week randomized, placeboâ€controlled, doubleâ€blind trial. Annals of Neurology, 2002, 52, 346-350.	5.3	372
314	Glutathione release from cultured brain cells: Multidrug resistance protein 1 mediates the release of GSH from rat astroglial cells. Journal of Neuroscience Research, 2002, 69, 318-326.	2.9	128
315	Diffusion-weighted MRI in patients with symptomatic internal carotid artery disease. Journal of Neurology, 2002, 249, 1168-1174.	3.6	31
316	Spectrum of phenotypes and genotypes in Parkinson's disease. Journal of Neurology, 2002, 249, 1-1.	3.6	10
317	Identification of inhibitor-of-differentiation 2 (Id2) as a modulator of neuronal apoptosis. Journal of Neurochemistry, 2002, 80, 755-762.	3.9	33
318	Effects of dopamine on the glutathione metabolism of cultured astroglial cells: implications for Parkinson's disease. Journal of Neurochemistry, 2002, 82, 458-467.	3.9	67
319	Neuron-Specific Expression of Therapeutic Proteins: Evaluation of Different Cellular Promoters in Recombinant Adenoviral Vectors. Molecular and Cellular Neurosciences, 2001, 17, 78-96.	2.2	152
320	Cascade of Caspase Activation in Potassium-Deprived Cerebellar Granule Neurons: Targets for Treatment with Peptide and Protein Inhibitors of Apoptosis. Molecular and Cellular Neurosciences, 2001, 17, 717-731.	2.2	77
321	The multidrug resistance protein MRP1 mediates the release of glutathione disulfide from rat astrocytes during oxidative stress. Journal of Neurochemistry, 2001, 76, 627-636.	3.9	153
322	Sensitivity to MPTP is not increased in Parkinson's diseaseâ€associated mutant αâ€synuclein transgenic mice. Journal of Neurochemistry, 2001, 77, 1181-1184.	3.9	125
323	Malonate-Induced Generation of Reactive Oxygen Species in Rat Strium Depends on Dopamine Release but Not on NMDA Receptor Activation. Journal of Neurochemistry, 2001, 73, 1329-1332.	3.9	58
324	Effectiveness of intravenous immunoglobin therapy in cerebellar ataxia associated with gluten sensitivity. Annals of Neurology, 2001, 50, 827-828.	5.3	74

#	Article	IF	CITATIONS
325	Apoptosis: its relevance to Parkinson's disease. Clinical Neuroscience Research, 2001, 1, 427-433.	0.8	18
326	Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. Journal of Neurochemistry, 2001, 77, 263-273.	3.9	89
327	Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10433-10438.	7.1	208
328	Glutathione, oxidative stress and neurodegeneration. FEBS Journal, 2000, 267, 4904-4911.	0.2	1,017
329	Evoked potentials in multiple systematrophy (MSA). Acta Neurologica Scandinavica, 2000, 101, 111-115.	2.1	28
330	Introduction: Targeted Modulation of Neuronal Apoptosis: A Doubleâ€Edged Sword?. Brain Pathology, 2000, 10, 273-275.	4.1	2
331	Neuroprotection by the Inhibition of Apoptosis. Brain Pathology, 2000, 10, 283-292.	4.1	203
332	Flupirtine and retigabine prevent l-glutamate toxicity in rat pheochromocytoma PC 12 cells. European Journal of Pharmacology, 2000, 400, 155-166.	3.5	32
333	Protection by Synergistic Effects of Adenovirus-Mediated X-Chromosome-Linked Inhibitor of Apoptosis and Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease. Journal of Neuroscience, 2000. 20. 9126-9134.	3.6	194
334	Nerve Conduction Studies in Multiple System Atrophy. European Neurology, 2000, 43, 221-223.	1.4	18
335	Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons. Neuroscience Letters, 2000, 282, 69-72.	2.1	38
336	Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochemistry International, 2000, 36, 489-497.	3.8	41
337	High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. Human Molecular Genetics, 1999, 8, 1169-1176.	2.9	69
338	Patterns of Age-related Shrinkage in Cerebellum and Brainstem Observed In Vivo Using Three-dimensional MRI Volumetry. Cerebral Cortex, 1999, 9, 712-721.	2.9	192
339	Exogenous Administration of Gangliosides Displaces GPI-anchored Proteins from Lipid Microdomains in Living Cells. Molecular Biology of the Cell, 1999, 10, 3187-3196.	2.1	95
340	Adenovirus-Mediated Gene Transfer of Inhibitors of Apoptosis Proteins Delays Apoptosis in Cerebellar Granule Neurons. Journal of Neurochemistry, 1999, 72, 292-301.	3.9	116
341	Glutathione depletion and neuronal cell death: the role of reactive oxygen intermediates and mitochondrial function. Brain Research, 1999, 826, 53-62.	2.2	166
342	Magnetic resonance imaging-based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Annals of Neurology, 1999, 45, 65-74.	5.3	255

#	Article	IF	CITATIONS
343	Caspases as treatment targets in stroke and neurodegenerative diseases. Annals of Neurology, 1999, 45, 421-429.	5.3	315
344	Differential effects of l-buthionine sulfoximine and ethacrynic acid on glutathione levels and mitochondrial function in PC12 cells. Neuroscience Letters, 1999, 264, 1-4.	2.1	69
345	MPP+ Inhibits Proliferation of PC12 Cells by a p21WAF1/Cip1-Dependent Pathway and Induces Cell Death in Cells Lacking p21WAF1/Cip1. Experimental Cell Research, 1999, 250, 75-85.	2.6	50
346	Magnetic resonance imaging–based volumetry differentiates idiopathic Parkinson's syndrome from multiple system atrophy and progressive supranuclear palsy. Annals of Neurology, 1999, 45, 65-74.	5.3	152
347	Molecular pathogenesis of movement disorders: are protein aggregates a common link in neuronal degeneration?. Current Opinion in Neurology, 1999, 12, 433-439.	3.6	33
348	Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia. Cell Death and Differentiation, 1998, 5, 847-857.	11.2	93
349	Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing. Cell Death and Differentiation, 1998, 5, 894-900.	11.2	52
350	A new semiautomated, three-dimensional technique allowing precise quantification of total and regional cerebellar volume using MRI. Magnetic Resonance in Medicine, 1998, 40, 143-151.	3.0	77
351	Endonucleolytic DNA fragmentation is not required for apoptosis of cultured rat cerebellar granule neurons. Neuroscience Letters, 1998, 245, 9-12.	2.1	17
352	Risk factors for idiopathic cerebellar ataxia of late onset. Journal of the Neurological Sciences, 1998, 160, 171-174.	0.6	9
353	Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain, 1998, 121, 1687-1693.	7.6	157
354	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyride Neurotoxicity Is Attenuated in Mice Overexpressing Bcl-2. Journal of Neuroscience, 1998, 18, 8145-8152.	3.6	193
355	Potassium Deprivation-Induced Apoptosis of Cerebellar Granule Neurons: Cytochrome c Release in the Absence of Altered Expression of Bcl-2 Family Proteins. Cellular Physiology and Biochemistry, 1998, 8, 194-201.	1.6	27
356	Induction of Nitric Oxide Synthase and Nitric Oxideâ€Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActorâ€Î±/Lipopolysaccharide. Journal of Neurochemistry, 1998, 71, 88-94.	3.9	186
357	Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 7606-7611.	7.1	279
358	Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: The effects of 3-acetylpyridine neurotoxicity. Neuroscience, 1997, 81, 721-734.	2.3	28
359	Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Research, 1997, 753, 157-162.	2.2	184
360	Title is missing!. Molecular and Cellular Biochemistry, 1997, 174, 193-197.	3.1	145

#	Article	IF	CITATIONS
361	Increased 3â€nitrotyrosine and oxidative damage in mice with a human copper/zinc superoxide dismutase mutation. Annals of Neurology, 1997, 42, 326-334.	5.3	244
362	Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease. Synapse, 1997, 26, 381-391.	1.2	34
363	Cooperative Interception of Neuronal Apoptosis by BCLâ€⊋ and BAGâ€1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species. Journal of Neurochemistry, 1997, 69, 2075-2086.	3.9	94
364	The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. , 1997, , 193-197.		48
365	Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases. Neuroscience, 1996, 71, 1043-1048.	2.3	150
366	INVOLVEMENT OF OXIDATIVE STRESS IN 3-NITROPROPIONIC ACID NEUROTOXICITY. Neurochemistry International, 1996, 29, 167-171.	3.8	131
367	Potassium Deprivation-Induced Apoptosis of Cerebellar Granule Neurons: A Sequential Requirement for New mRNA and Protein Synthesis, ICE-Like Protease Activity, and Reactive Oxygen Species. Journal of Neuroscience, 1996, 16, 4696-4706.	3.6	330
368	Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones. NeuroReport, 1996, 7, 921-923.	1.2	149
369	NGF, BDNF and NT-5, but not NT-3 protect against MPP+ toxicity and oxidative stress in neonatal animals. Brain Research, 1996, 713, 178-185.	2.2	97
370	Non-Invasive Neurochemical Analysis of Focal Excitotoxic Lesions in Models of Neurodegenerative Illness Using Spectroscopic Imaging. Journal of Cerebral Blood Flow and Metabolism, 1996, 16, 450-461.	4.3	80
371	Striatal Malonate Lesions Are Attenuated in Neuronal Nitric Oxide Synthase Knockout Mice. Journal of Neurochemistry, 1996, 67, 430-433.	3.9	72
372	Role of nitric oxide in neurodegenerative diseases. Current Opinion in Neurology, 1995, 8, 480-486.	3.6	95
373	Improved Therapeutic Window for Treatment of Histotoxic Hypoxia with a Free Radical Spin Trap. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 948-952.	4.3	57
374	Basic Fibroblast Growth Factor Protects against Excitotoxicity and Chemical Hypoxia in Both Neonatal and Adult Rats. Journal of Cerebral Blood Flow and Metabolism, 1995, 15, 619-623.	4.3	83
375	Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Experimental Neurology, 1995, 132, 279-283.	4.1	101
376	Neuroprotective Effects of Free Radical Scavengers and Energy Repletion in Animal Models of Neurodegenerative Disease. Annals of the New York Academy of Sciences, 1995, 765, 100-110.	3.8	25
377	Inhibition of Neuronal Nitric Oxide Synthase by 7â€Nitroindazole Protects Against MPTPâ€Induced Neurotoxicity in Mice. Journal of Neurochemistry, 1995, 64, 936-939.	3.9	377
378	Involvement of Free Radicals in Excitotoxicity In Vivo. Journal of Neurochemistry, 1995, 64, 2239-2247.	3.9	290

#	Article	IF	CITATIONS
379	Absence of SCA1 mutation in idiopathic cerebellar ataxia Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1439-1440.	1.9	6
380	Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT Journal of Neurology, Neurosurgery and Psychiatry, 1994, 57, 1047-1056.	1.9	198
381	Oculomotor abnormalities and MRI findings in idiopathic cerebellar ataxia. Journal of Neurology, 1994, 241, 234-241.	3.6	28
382	Coenzyme Q ₁₀ and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate. Annals of Neurology, 1994, 36, 882-888.	5.3	183
383	3-Acetylpyridine Produces Age-Dependent Excitotoxic Lesions in Rat Striatum. Journal of Cerebral Blood Flow and Metabolism, 1994, 14, 1024-1029.	4.3	37
384	Aminooxyacetic acid striatal lesions attenuated by 1,3-butanediol and coenzyme Q10. Neuroscience Letters, 1994, 177, 58-62.	2.1	22
385	Systemic or Local Administration of Azide Produces Striatal Lesions by an Energy Impairment-Induced Excitotoxic Mechanism. Experimental Neurology, 1994, 129, 175-182.	4.1	38
386	Malonate produces striatal lesions by indirect NMDA receptor activation. Brain Research, 1994, 647, 161-166.	2.2	90
387	Mitochondrial dysfunction in movement disorders. Current Opinion in Neurology, 1994, 7, 333-339.	3.6	75
388	Superoxide Dismutase Activity, Oxidative Damage, and Mitochondrial Energy Metabolism in Familial and Sporadic Amyotrophic Lateral Sclerosis. Journal of Neurochemistry, 1993, 61, 2322-2325.	3.9	555
389	Muscarinic desensitization after septal lesions in rat hippocampus: Evidence for the involvement of G-proteins. Neuroscience, 1992, 47, 95-103.	2.3	13
390	Verdachtsdiagnose: Demenz – Was ist nun zu tun?. , 0, , .		0
391	Erythropoietin Enhances Post-ischemic Migration and Phagocytosis and Alleviates the Activation of Inflammasomes in Human Microglial Cells. Frontiers in Cellular Neuroscience, 0, 16, .	3.7	2